All > Thyroid Cancer > Thyroid

Sirolimus for Medullary Thyroid Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
University of Michigan Cancer Center, Ann Arbor, MIMedullary Thyroid CancerSirolimus - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study the effects of two drugs, Cyclophosphamide and Sirolimus, on thyroid cancer that has spread.

Eligible Conditions
  • Metastatic Medullary Thyroid Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Stereotactic Body Radiation Therapy
1
single dose of CART-GFRa4 cells
1
Radiation Therapy

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Patients will be followed until death or up to 2 years

Day 30
The number of patients that experience toxicity
Year 2
Median progression free survival time
Percentage of patients that respond to treatment
Year 2
Median overall survival time

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Stereotactic Body Radiation Therapy
1
single dose of CART-GFRa4 cells
1
Radiation Therapy

Trial Design

1 Treatment Group

Cyclophosphamide and Sirolimus
1 of 1

Experimental Treatment

19 Total Participants · 1 Treatment Group

Primary Treatment: Sirolimus · No Placebo Group · Phase 2

Cyclophosphamide and SirolimusExperimental Group · 2 Interventions: Sirolimus, Cyclophosphamide · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sirolimus
FDA approved
Cyclophosphamide
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: patients will be followed until death or up to 2 years

Who is running the clinical trial?

University of Michigan Rogel Cancer CenterLead Sponsor
270 Previous Clinical Trials
18,136 Total Patients Enrolled
Paul Swiecicki, M.D.Principal InvestigatorUniversity of Michigan Rogel Cancer Center
3 Previous Clinical Trials
84 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 11 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Frequently Asked Questions

What studies have been done on the long-term effects of Sirolimus?

"Sirolimus has received a score of 2 from our team at Power. This is because, although there is data supporting its safety, this medication has not yet been proven effective in clinical trials." - Anonymous Online Contributor

Unverified Answer

What is the total subject pool for this experiment?

"According to the clinicaltrials.gov website, this clinical trial is still looking for patients. This particular study was first posted on April 27th, 2017 and received its most recent update on August 15th, 2022. So far, 19 patients have been enrolled at 1 site." - Anonymous Online Contributor

Unverified Answer

For what purpose is Sirolimus most often prescribed?

"Sirolimus is a medication that's frequently used in organ transplantation procedures. Additionally, it has shown to be helpful for patients with multiple sclerosis, leukemia, myelocytic, acute conditions, and retinoblastoma." - Anonymous Online Contributor

Unverified Answer

Are new participants being accepted for this experiment?

"The online registry, clinicaltrials.gov, shows that this trial is open and looking for patients. This particular study was first advertised on April 27th, 2017 with the most recent update being from August 15th, 2022." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top